By Esther Onyegbula
The Association of Community Pharmacists of Nigeria (ACPN) has questioned the statutory authority of the Edo State Consumer Protection Committee to undertake pharmaceutical regulatory enforcement, insisting that specialised drug regulation must be carried out by legally empowered agencies.
The association, which raised concerns over the committee’s activities under the leadership of its Chairman, Mr Osaro Culture Iyamu, accused it of possible regulatory overreach and demanded clarification from the Edo State Government on the legal instrument empowering the committee to exercise such functions.
ACPN also challenged Iyamu to provide verifiable evidence within 24 hours to substantiate his reported claim that Camosunate is a banned medicinal product in Nigeria, threatening legal action if he fails to do so.
In a statement signed by its National Chairman, Pharm. Ambrose Igwekamma Ezeh, MAW, the association said its position was not an attempt to undermine efforts to rid the country of counterfeit, adulterated, substandard and expired medicines, but a call for such interventions to be conducted within the confines of the law.
It described the reported declaration that Camosunate is banned in Nigeria as seriously misleading, noting that a verification of the National Agency for Food and Drug Administration and Control (NAFDAC) official Greenbook identified Camosunate Children Powder, with Registration Number 04-7908, manufactured by Front Pharmaceuticals PLC and marketed by Geneith Pharmaceuticals Limited, as an active registered medicinal product.
According to the association, the product’s registration was approved on November 26, 2025, and remains valid until November 25, 2030.
Describing the information as an official regulatory record rather than industry rumour or personal opinion, ACPN challenged Iyamu to produce, within 24 hours of its press statement, an authentic NAFDAC prohibition, suspension, withdrawal or cancellation notice establishing that the specific Camosunate formulation he declared banned is prohibited in Nigeria.
It demanded an immediate public retraction and apology if the committee chairman fails to provide verifiable evidence within the stipulated period.
The association warned that it would not hesitate to pursue appropriate legal remedies over any demonstrably false, damaging and unjustified public statements concerning registered medicinal products and pharmacy practitioners, adding that all applicable legal remedies remained expressly reserved.
Beyond the Camosunate controversy, ACPN raised concerns over the reported enforcement action involving ALSO CARE Pharmacy in Evbuodia community, along Airport Road, Benin City, and the public allegations made against the establishment.
It called for the transparent disclosure of the products allegedly seized, their registration particulars and the independent regulatory evidence supporting claims that the medicines were counterfeit or prohibited.
The association maintained that no pharmacy should be publicly condemned on the basis of unverified assertions.
Explaining its position on the committee’s statutory jurisdiction, ACPN referenced the Pharmacy Council of Nigeria (Establishment) Act 2022, particularly Sections 22, 31 and 32, which provide the statutory framework for pharmaceutical premises registration, inspection and enforcement through designated Pharmaceutical Inspection Officers.
It also cited Sections 7 and 8 of the Counterfeit and Fake Drugs and Unwholesome Processed Foods (Miscellaneous Provisions) Act, Cap C34, Laws of the Federation of Nigeria 2004, which prescribe the constitution and powers of the State Task Force.
According to ACPN, such powers cannot automatically be assumed by an ordinary State Consumer Protection Committee without evidence of the requisite statutory constitution and appointments.
The association further referenced Section 5 of the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria 2004, which establishes the agency’s statutory responsibility for the regulation of medicinal products.
It argued that a general consumer-protection mandate does not, in itself, confer specialised pharmaceutical regulatory powers.
Consequently, ACPN outlined six demands, including the immediate production of authentic NAFDAC evidence supporting the alleged Camosunate ban, a public retraction and apology if the claim cannot be substantiated, and disclosure by the Edo State Government of the committee’s enabling instrument.
It also demanded disclosure of any Federal Ministerial appointment establishing the committee as a State Task Force under Section 7 of the Counterfeit and Fake Drugs Act.
Other demands include an end to pharmaceutical enforcement activities undertaken without demonstrable statutory authority and respect for the respective regulatory mandates of NAFDAC and the Pharmacy Council of Nigeria.
The association appealed to the Edo State Governor, Senator Monday Okpebholo, to intervene urgently to ensure institutional accountability and prevent further jurisdictional conflicts capable of undermining public confidence in the state’s healthcare delivery system.
Reaffirming its commitment to protecting Nigerians from dangerous medicines, ACPN stressed that consumer protection must not become a licence for misinformation, administrative arbitrariness or regulatory intimidation.
It maintained that public officials must be accountable for their statements, regulatory authority must be established by law, and professional pharmacy practice must be protected through the same legal framework.
The association vowed to defend these principles through every legitimate institutional and legal channel available.

No comments yet. Start the conversation.